摘要
目的研究共病对肺癌患者住院费用的影响,为肺癌共病患者住院费用的管理与控制提供理论依据。方法从医院电子病案系统中抽取2014—2021年ICD编码为C34肺癌患者的住院病例,运用回归分析探讨共病对肺癌患者住院费用的影响程度。结果与单纯肺癌患者相比,共1种疾病患者住院费用增加了0.011个单位(β=0.011,P<0.05),共2种疾病患者住院费用增加了0.021个单位(β=0.021,P<0.05),共3种疾病患者住院费用增加了0.049个单位(β=0.049,P<0.05)。住院时间每增加1 d,住院费用增加0.016个单位(β=0.016,P<0.05)。结论共病影响肺癌患者住院费用,共病越多,住院费用越高。
Objective To study the effect of co-morbidity on hospitalization cost of lung cancer patients,and to provide theoretical basis for the management and control of hospitalization cost of lung cancer patients with co-morbidity.Methods Inpatient cases of lung cancer patients with ICD code C34 from 2014 to 2021 were extracted from the hospital electronic medical case system,and regression analysis was applied to explore the degree of influence of co-morbidities on the hospitalization costs of lung cancer patients.Results Compared with patients with lung cancer alone,hospitalization costs increased by 0.011 units for patients with 1 co-morbidity(β=0.011,P<0.05),0.021 units for patients with 2 co-morbidities(β=0.021,P<0.05),and 0.049 units for patients with 3 co-morbidities(β=0.049,P<0.05).Hospitalization costs increased by 0.016 units for each 1-d increase in hospitalization time(β=0.016,P<0.05).Conclusion Co-morbidities affect the hospitalization cost of lung cancer patients,and the more co-morbidities,the higher the hospitalization cost.
作者
金秀
匡莹
JIN Xiu;KUANG Ying(Department of Personnel,Nantong Cancer Hospital,Nantong,Jiangsu Province,226000 China)
出处
《中国卫生产业》
2022年第19期139-142,195,共5页
China Health Industry
关键词
肺癌
共病
住院费用
Lung cancer
Co-morbidity
Hospitalization cost